Patents by Inventor Lisa WELLINGER

Lisa WELLINGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TARGETING CD117
    Publication number: 20260258124
    Abstract: The present disclosure relates to antibodies and antibody fragments that are specific for CD117. The antibodies are improved versions of state-of-the art antibodies. In addition to a sophisticated humanization campaign, the antibodies were also engineered to remove several detrimental motifs within the CDR region without losing any beneficial properties. The antibodies are useful for the treatment of diseases associated with CD117.
    Type: Application
    Filed: July 7, 2023
    Publication date: September 3, 2026
    Inventors: Stefanie URLINGER, Anna CAMUS, Rosalba LEPORE, Alessandro SINOPOLI, Amélie WIEDERKEHR, Lukas JEKER, Frank LEHMANN, Anna HAYDN, Mathilde TESTUT, Lisa WELLINGER, Laura GARCIA PRAT, Emiel TEN BUREN, Melanie HUG
  • Antibodies Targeting ActRIIA and ActRIIB
    Publication number: 20250243286
    Abstract: The present disclosure relates to antibodies and antibody fragments that are specific for ActRIIA and ActRIIB. The antibodies are improved versions of bimagrumab. Antibodies of the present invention have an improved affinity against ActRIIA, translating into improved in vitro potency and efficacy, an improved PK and PD profile and a higher stability making the antibodies suitable for s.c. administration. Optionally they carry Fc modifications making the antibodies safe for prolonged treatments.
    Type: Application
    Filed: April 14, 2025
    Publication date: July 31, 2025
    Inventors: Christian KUNZ, Amélie WIEDERKEHR, Lisa WELLINGER, Anne Laure LAINÉ, Emily RADKE, Caitlin STEIN, Arvind SIVASUBRAMANIAN
  • Antibodies Targeting ActRIIA and ActRIIB
    Publication number: 20250109208
    Abstract: The present disclosure relates to antibodies and antibody fragments that are specific for ActRIIA and ActRIIB. The antibodies are improved versions of bimagrumab. Antibodies of the present invention have an improved affinity against ActRIIA, translating into improved in vitro potency and efficacy, an improved PK and PD profile and a higher stability making the antibodies suitable for s.c. administration. Optionally they carry Fc modifications making the antibodies safe for prolonged treatments.
    Type: Application
    Filed: November 13, 2024
    Publication date: April 3, 2025
    Inventors: Christian KUNZ, Amélie WIEDERKEHR, Lisa WELLINGER, Anne Laure LAINÉ, Emily RADKE, Caitlin STEIN, Arvind SIVASUBRAMANIAN
  • DISCERNIBLE CELL SURFACE PROTEIN VARIANTS OF CD117 FOR USE IN CELL THERAPY
    Publication number: 20250057951
    Abstract: The present disclosure relates to the use of cells having discernible surface protein with engineered or naturally occurring mutation(s) but functional surface protein for use in therapy. The present invention also relates to the use of cells having discernible CD117 surface protein variants but functional surface protein for use in therapy, in particular adoptive cell therapy.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 20, 2025
    Inventors: Stefanie URLINGER, Rosalba LEPORE, Lukas JEKER, Amélie WIEDERKEHR, Alessandro SINOPOLI, Anna CAMUS, Lisa WELLINGER, Romina MATTER-MARONE